Published in Arch Intern Med on July 22, 2002
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy | NCT00108485
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
The metabolic syndrome. Endocr Rev (2008) 5.33
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J (2013) 4.87
A comprehensive review on metabolic syndrome. Cardiol Res Pract (2014) 3.47
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM (2009) 2.14
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes (2015) 1.33
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2010) 1.21
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Nicotinic acid: an old drug with a promising future. Br J Pharmacol (2007) 1.04
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol (2009) 0.99
Nitric oxide: considerations for the treatment of ischemic stroke. J Cereb Blood Flow Metab (2012) 0.97
Managing dyslipidemia in chronic kidney disease. J Gen Intern Med (2004) 0.96
HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther (2012) 0.92
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin Proc (2010) 0.91
Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol (2007) 0.90
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care (2012) 0.89
Ocular Effects of Niacin: A Review of the Literature. Med Hypothesis Discov Innov Ophthalmol (2015) 0.88
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag (2009) 0.87
Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab (2006) 0.87
Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol (2012) 0.86
New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging (2008) 0.83
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis (2013) 0.81
Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats. J Lipid Res (2015) 0.80
Water-soluble vitamins in people with low glomerular filtration rate or on dialysis: a review. Semin Dial (2013) 0.80
Diabetes: managing dyslipidaemia. BMJ Clin Evid (2008) 0.79
Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes (2014) 0.79
Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy. Cardiorenal Med (2012) 0.79
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag (2007) 0.78
Niacin increased glucose, insulin, and C-peptide levels in sedentary nondiabetic postmenopausal women. Int J Womens Health (2014) 0.78
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Drug Healthc Patient Saf (2010) 0.78
Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud (2013) 0.77
Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Can J Cardiol (2010) 0.77
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. J Clin Hypertens (Greenwich) (2009) 0.77
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin. Vasc Health Risk Manag (2008) 0.77
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Ther Clin Risk Manag (2010) 0.77
Current Drug Options for Raising HDL Cholesterol. Curr Treat Options Cardiovasc Med (2005) 0.77
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int J Gen Med (2014) 0.76
Are the effects of nicotinic acid on insulin resistance precipitated by abnormal phosphorous metabolism? Lipids Health Dis (2004) 0.76
Pilot study on the safety and tolerability of extended release niacin for HIV-infected patients with hypertriglyceridemia. Hawaii Med J (2010) 0.76
Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. Curr Ther Res Clin Exp (2006) 0.75
Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments. J Pharmacokinet Pharmacodyn (2017) 0.75
The use of niacin in diabetes mellitus. Arch Intern Med (2003) 0.75
Effect of Nicotinic Acid (Vitamin B3 or Niacin) on the lipid profile of diabetic and non - diabetic rats. Pak J Med Sci (2013) 0.75
The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a). Cholesterol (2010) 0.75
Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. Clin Med Insights Cardiol (2011) 0.75
Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf (2012) 0.75
Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. Drugs Aging (2012) 0.75
Hyperlipidemia medication management in patients admitted for a myocardial infarction. Pharm Pract (Granada) (2011) 0.75
The Effects of Tetrahydro-iso-alpha Acids and Niacin on Monocyte-Edothelial Cell Interactions and Flow-mediated Vasodilation. Glob Adv Health Med (2012) 0.75
Facts and ideas from anywhere. Proc (Bayl Univ Med Cent) (2002) 0.75
Effect of combined therapy of diabinese and nicotinic acid on liver enzymes in rabbits with dithizone-induced diabetes. J Exp Pharmacol (2010) 0.75
[Risk adapted therapy of vascular diseases--basic therapy of dys- and hyperlipoproteinemia]. Z Kardiol (2005) 0.75
Hypertriglyceridemia-why, when and how should it be treated? Z Kardiol (2005) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis (2007) 2.84
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract (2003) 2.42
Statins: panacea for sepsis? Lancet Infect Dis (2006) 2.32
An assessment of statin safety by muscle experts. Am J Cardiol (2006) 2.16
Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Assessment of group versus individual diabetes education: a randomized study. Diabetes Care (2002) 2.02
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Consensus report of the coalition for clinical research-self-monitoring of blood glucose. J Diabetes Sci Technol (2008) 1.81
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Migration and its impact on adiposity and type 2 diabetes. Nutrition (2007) 1.75
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
The effect of a structured behavioral intervention on poorly controlled diabetes: a randomized controlled trial. Arch Intern Med (2011) 1.71
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect (2008) 1.53
Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes (2010) 1.52
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs (2013) 1.43
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med (2010) 1.37
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol (2009) 1.36
Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J (2007) 1.36
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood (2008) 1.26
Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol (2013) 1.24
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2008) 1.21
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther (2010) 1.18
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17
Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. Diabetes Care (2003) 1.16
Do older adults aged 60-75 years benefit from diabetes behavioral interventions? Diabetes Care (2013) 1.16
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 1.15
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.15
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis (2007) 1.13
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care (2012) 1.11
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol (2002) 1.10
Look who's (not) talking: diabetic patients' willingness to discuss self-care with physicians. Diabetes Care (2012) 1.09
Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol (2010) 1.09
Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis (2002) 1.08
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. Circulation (2002) 1.07
Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Part Fibre Toxicol (2010) 1.07
Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. Ethn Dis (2007) 1.06
Limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. J Am Coll Cardiol (2013) 1.06
Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets. Postgrad Med (2005) 1.05
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05
Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control. Diabetes Technol Ther (2005) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol (2010) 1.04
Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. Diabetes Educ (2006) 1.03
Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite. Blood (2009) 1.02
Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation (2004) 1.00
Activation of factor XI by products of prothrombin activation. Blood (2011) 0.99
Variable contributions of fat content and distribution to metabolic syndrome risk factors. Metab Syndr Relat Disord (2008) 0.99
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res (2011) 0.98
North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. J Dent Educ (2011) 0.97
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther (2010) 0.96